{"id":7952,"date":"2026-06-03T20:14:16","date_gmt":"2026-06-03T20:14:16","guid":{"rendered":"https:\/\/healthnews.zone\/?p=7952"},"modified":"2026-06-03T20:14:17","modified_gmt":"2026-06-03T20:14:17","slug":"a-simple-blood-test-could-transform-how-we-detect-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/healthnews.zone\/?p=7952","title":{"rendered":"A Simple Blood Test Could Transform How We Detect Alzheimer’s Disease"},"content":{"rendered":"\n

Scientists may be on the verge of a breakthrough that could dramatically change how Alzheimer’s disease is diagnosed and monitored. New research published in JAMA Neurology<\/em> suggests that a simple blood test may be able to detect and even stage Alzheimer’s disease with an accuracy that closely matches advanced brain imaging scans. If confirmed in larger studies, the approach could make Alzheimer’s testing faster, cheaper, and far more accessible to millions of people.<\/p>\n\n\n\n

What Is Alzheimer’s Disease?<\/strong><\/p>\n\n\n\n

Alzheimer’s disease is a neurodegenerative disorder that gradually destroys memory, thinking skills, and eventually the ability to perform everyday tasks. It is characterized by the buildup of two abnormal proteins in the brain: amyloid-beta plaques and tau tangles. These proteins accumulate over many years, damaging brain cells and disrupting communication between neurons.<\/p>\n\n\n\n

Researchers now understand that Alzheimer’s develops in stages. The disease often begins long before symptoms appear. Amyloid plaques accumulate first, followed by the spread of tau tangles into increasingly larger areas of the brain. As tau pathology expands, cognitive impairment becomes more severe.<\/p>\n\n\n\n

Why Diagnosing Alzheimer’s Is Difficult<\/strong><\/p>\n\n\n\n

Today, accurately diagnosing Alzheimer’s often requires specialized testing that can be expensive, invasive, or both.<\/p>\n\n\n\n

One common method is positron emission tomography, or PET scanning. These scans allow doctors to visualize amyloid plaques and tau tangles in the brain. PET scans are highly informative but require specialized equipment, radioactive tracers, and substantial infrastructure. They are not widely available in many communities and can be costly for patients and healthcare systems.<\/p>\n\n\n\n

Another option involves analyzing cerebrospinal fluid collected through a spinal tap. While effective, spinal taps are invasive and many patients are reluctant to undergo the procedure. Researchers have therefore been searching for a simpler way to identify the biological signs of Alzheimer’s.<\/p>\n\n\n\n

The Alzheimer’s Association has emphasized the need for a more scalable and globally accessible testing method that could bring biological staging into routine clinical practice.<\/p>\n\n\n\n

The New Blood Test Approach<\/strong><\/p>\n\n\n\n

The new study focused on two biomarkers found in blood: %p-tau217 and eMTBR-tau243. Both are related to the tau protein that plays a central role in Alzheimer’s disease.<\/p>\n\n\n\n

Researchers found that these two biomarkers provide complementary information. The %p-tau217 marker appears particularly useful for detecting earlier disease changes associated with amyloid pathology. The eMTBR-tau243 marker becomes especially valuable in identifying more advanced stages of tau accumulation. When combined, the two biomarkers provide a more complete picture of disease progression than either marker alone.<\/p>\n\n\n\n

The goal was ambitious: create a blood-based model capable of reproducing the same staging system currently obtained through sophisticated PET brain scans.<\/p>\n\n\n\n

The study was led by Dr. Gemma Salvad\u00f3 and colleagues and involved collaboration between researchers in Sweden and the United States.<\/p>\n\n\n\n

The primary research group came from the BioFINDER-2 study, which recruited participants through Sk\u00e5ne University Hospital and Hospital of \u00c4ngelholm in Sweden. Researchers then validated their findings using an independent group of participants from the Knight Alzheimer Disease Research Center at Washington University in St. Louis.<\/p>\n\n\n\n

The study analyzed data collected over several years and included participants ranging from cognitively healthy individuals to people with mild cognitive impairment, Alzheimer’s dementia, and other neurodegenerative diseases.<\/p>\n\n\n\n

How the Study Was Performed<\/strong><\/p>\n\n\n\n

The research team examined 872 participants in the BioFINDER-2 cohort and then tested their model on an additional 156 participants from the Knight Alzheimer Disease Research Center. Together, the study included more than 1,000 individuals.<\/p>\n\n\n\n

Each participant underwent blood testing and extensive Alzheimer’s evaluations. Researchers compared the blood biomarker results against established PET-based staging systems that measure amyloid and tau pathology in the brain.<\/p>\n\n\n\n

The team used statistical modeling to determine whether blood biomarker levels could accurately predict the biological stage that would normally be identified through PET imaging. Importantly, the researchers also compared the blood results against cognitive testing, brain imaging, and in some cases, autopsy-confirmed Alzheimer’s pathology.<\/p>\n\n\n\n

The Results Were Remarkably Strong<\/strong><\/p>\n\n\n\n

The blood-based model demonstrated what researchers described as “high concordance” with PET-based staging.<\/p>\n\n\n\n

In the main BioFINDER-2 cohort, the blood test achieved a concordance index of 0.91 when compared with PET-based biological staging. In the independent validation group, the concordance index was also 0.91. These results suggest that the blood test was highly successful at reproducing the staging information normally obtained from PET scans.<\/p>\n\n\n\n

The blood test also showed strong agreement with patients’ clinical status. Concordance with clinical stages reached 0.84 in the primary cohort and 0.86 in the validation cohort.<\/p>\n\n\n\n

Perhaps even more impressive, the researchers examined a subgroup of patients who later underwent autopsy. In that analysis, plasma staging showed extremely strong alignment with confirmed Alzheimer’s pathology, achieving an area under the curve of 0.96.<\/p>\n\n\n\n

The two-biomarker model also significantly outperformed a simpler model that relied only on %p-tau217. The addition of eMTBR-tau243 proved especially important for identifying intermediate stages of disease progression.<\/p>\n\n\n\n

If future studies confirm these findings, the blood test could do much more than simply indicate whether Alzheimer’s is present.<\/p>\n\n\n\n

The test may allow doctors to determine how far the disease has progressed biologically, much like cancer staging. Researchers found that plasma stages closely tracked the expected progression from amyloid accumulation to tau spread, cognitive decline, and brain atrophy.<\/p>\n\n\n\n

This information could help physicians identify patients who are most likely to benefit from emerging Alzheimer’s treatments. It could also improve enrollment in clinical trials by ensuring participants are at the appropriate stage of disease.<\/p>\n\n\n\n

Dr. Randy D’Amico of Northwell Lenox Hill Hospital, who was not involved in the research, highlighted the potential impact.<\/p>\n\n\n\n

“If the data hold up in bigger studies, I think it can really dramatically expand access to biological Alzheimer’s testing, which is a big deal,” he said. He added that better staging could help doctors “better select targets for therapies” and potentially prevent irreversible brain damage or improve outcomes.<\/p>\n\n\n\n

A Potential Game Changer<\/strong><\/p>\n\n\n\n

Researchers caution that more work is needed before the test becomes part of routine clinical care. Larger and more diverse patient populations must be studied, and the current laboratory methods still need to become easier and more scalable.<\/p>\n\n\n\n

Still, the implications are enormous. Instead of requiring expensive brain scans or invasive spinal taps, a physician could someday order a simple blood draw that provides detailed information about a patient’s Alzheimer’s disease stage.<\/p>\n\n\n\n

For a disease that affects millions of people worldwide and often goes undetected until significant brain damage has already occurred, that possibility represents one of the most promising advances in Alzheimer’s research in years.<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Scientists may be on the verge of a breakthrough that could dramatically change how Alzheimer’s disease is diagnosed and monitored. New research published in JAMA Neurology suggests that a simple blood test may be able to detect and even stage Alzheimer’s disease with an accuracy that closely matches advanced brain imaging scans. If confirmed in larger studies, the approach could make Alzheimer’s testing faster, cheaper, and far more accessible to millions of people. What Is Alzheimer’s Disease? Alzheimer’s disease is […]<\/p>\n","protected":false},"author":2,"featured_media":7954,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,9],"tags":[],"class_list":["post-7952","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-anti-aging","category-mental-health"],"_links":{"self":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7952"}],"version-history":[{"count":1,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7952\/revisions"}],"predecessor-version":[{"id":7953,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7952\/revisions\/7953"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/media\/7954"}],"wp:attachment":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}